• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

376_981be_rev-1

Celyad Oncology Announces April 2021 Conference Schedule

April 1, 2021
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

March 31, 2021
READ THE PRESS RELEASE

Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights

March 24, 2021
READ THE PRESS RELEASE

Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

March 18, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces March 2021 Conference Schedule

March 1, 2021
READ THE PRESS RELEASE

Letter to Shareholders – February 2021

February 10, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces February 2021 Conference Schedule

February 2, 2021
READ THE PRESS RELEASE

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

January 18, 2021
READ THE PRESS RELEASE

Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors

January 11, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital

January 7, 2021
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology@CelyadSA·
15 Apr

What are the differences between CAR T and CAR NK therapies? Learn more from our new NK vs #TCell fact sheet available in our Media Center by the following link: https://bit.ly/3ad3dHt

Celyad Oncology@CelyadSA·
13 Apr

#DYK we are using two proprietary technologies for our #allogeneic CAR T therapies? Click here to discover how TIM and shRNA are enhancing our clinical candidates: https://bit.ly/2Rw9KXh

View All

Stay informed about the latest news!

Sign up FOR our newsletter

Please enter a valid email address.
Submit

Thanks for subscribing! Please check your email for further instructions.

Something went wrong. Please check your entries and try again.

By clicking on “send”, you accept that your data will be sent to us and processed by our provider in order to send you our newsletter. You can find more information on how we process your data in our Privacy Policy.

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy